immuno-oncology

Gut stomach

Biotech

Gilead, Arcus keep TIGIT dream alive with 27-month OS data

Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months.

James Waldron Oct 13, 2025 7:05am

Graphic of a fork in the road with arrows pointing in either direction

Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm

Bicycle bike ride travel

Bicycle lays off staff as Genentech rides away from R&D pact

Aug 8, 2025 8:50am

HKEX

Leads Biolabs hits Hong Kong stock exchange in $189M IPO

Jul 25, 2025 10:59am

Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Pfizer CEO makes case for $6B bet on 'fabulous' bispecific

Jun 10, 2025 9:56am

Berger

To Gilead's new CMO, pipeline diversification is key

Jun 9, 2025 10:00am